Bio-Rad Laboratories BIO Clinical Diagnostics — Depreciation, Depletion and Amortization
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Bio-Rad Laboratories in its filing.
Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.
The official record: Bio-Rad Laboratories’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Bio-Rad Laboratories's clinical diagnostics — depreciation, depletion and amortization.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Bio-Rad Laboratories's clinical diagnostics — depreciation, depletion and amortization?
- Bio-Rad Laboratories (BIO) reported clinical diagnostics — depreciation, depletion and amortization of $22.6M in Q1 2026.
- How has Bio-Rad Laboratories's clinical diagnostics — depreciation, depletion and amortization changed year-over-year?
- Bio-Rad Laboratories's clinical diagnostics — depreciation, depletion and amortization increased by 7.1% year-over-year, from $21.1M to $22.6M.
- What is the long-term trend for Bio-Rad Laboratories's clinical diagnostics — depreciation, depletion and amortization?
- Over 4 years (2021 to 2025), Bio-Rad Laboratories's clinical diagnostics — depreciation, depletion and amortization has grown at a 2.2% compound annual growth rate (CAGR), from $82.8M to $90.4M.
- What does clinical diagnostics — depreciation, depletion and amortization mean?
- The non-cash expense allocated to the Clinical Diagnostics segment for the wear and tear of tangible assets and the amortization of intangible assets over their useful lives. This reflects the consumption of capital investments.